Targeted Drugs in Chronic Lymphocytic Leukemia 2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 15 March 2025 | Viewed by 99
Special Issue Editor
Interests: CLL; precision therapies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the Special Issue "Targeted Drugs in Chronic Lymphocytic Leukemia" (https://www.mdpi.com/journal/cancers/special_issues/Targeted_Chronic).
Over the past decade, the treatment of CLL has transformed with the emergence of novel targeted therapies. Recent clinical advances have successfully tested newer generation drugs and combination therapies.
We are pleased to invite you to contribute to this Special Issue on Targeted Drugs in Chronic Lymphocytic Leukemia. We are interested in receiving high-quality articles, including basic, translational, and clinical studies. This Special Issue aims to highlight the importance of using the targeted therapies currently available in CLL, as well as research on the development of new agents and basic research into novel targetable pathways.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: kinase targeted agents (BTK, PI3K, SYK), BCL2-family targeted agents, other small molecules, monoclonal antibodies, antibody–drug conjugates, bi-specific antibodies, and immunotherapies, including CAR-T cell therapies. Please spread the word to all of your colleagues!
I look forward to receiving your contributions.
Dr. Justin Taylor
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CLL
- targeted therapies
- precision therapy
- B-cell
- BTK
- BCL2
- PI3K
- SYK
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
